The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner

Oncogene

Volumn 33, Issue 46, 2014, Pages 5360-5369

  Sun, J ^a   Mohlin, S ^a   Lundby, A ^b   Kazi, J U ^a   Hellman, U ^c   Pahlman S ^a   Olsen, J V ^b   Ronnstrand L ^a  

^a LUND UNIVERSITY   (Sweden)

^b University of Copenhagen   (Denmark)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

Author keywords

c Kit; c Kit D816V; cell transformation; p110 ; phosphorylation; PI3 kinase

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ADENINE; CHROMONE DERIVATIVE; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN BINDING; QUINAZOLINE DERIVATIVE; SERINE; STEM CELL FACTOR RECEPTOR; TYROSINE;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; DRUG EFFECTS; FEMALE; GENETICS; INBRED MOUSE STRAIN; METABOLISM; MISSENSE MUTATION; NUDE MOUSE; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ADENINE; ANIMALS; BINDING SITES; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CERCOPITHECUS AETHIOPS; CHROMONES; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; COS CELLS; FEMALE; MICE, INBRED STRAINS; MICE, NUDE; MORPHOLINES; MUTATION, MISSENSE; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-KIT; QUINAZOLINES; RNA INTERFERENCE; SERINE; TYROSINE;

EID: 85027922661     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.479     Document Type: Article

References (43)

1. Lennartsson J, Rönnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev 2012; 92: 1619–1649. DOI: 10.1152/physrev.00046.2011
2. Serve H, Yee NS, Stella G, Sepp-Lorenzino L, Tan JC, Besmer P. Differential roles of PI3-kinase and Kit tyrosine 821 in Kit receptor-mediated proliferation, survival and cell adhesion in mast cells. EMBO J 1995; 14: 473–483. DOI: 10.1002/j.1460-2075.1995.tb07023.x
3. Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 2009; 21: 199–208. DOI: 10.1016/j.ceb.2008.12.007
4. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ et al. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 1997; 94: 4330–4335. DOI: 10.1073/pnas.94.9.4330
5. Eickholt BJ, Ahmed AI, Davies M, Papakonstanti EA, Pearce W, Starkey ML et al. Control of axonal growth and regeneration of sensory neurons by the p110delta PI 3-kinase. PLoS One 2007; 2: e869. DOI: 10.1371/journal.pone.0000869
6. Sawyer C, Sturge J, Bennett DC, O'Hare MJ, Allen WE, Bain J et al. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res 2003; 63: 1667–1675.
7. Arcaro A, Khanzada UK, Vanhaesebroeck B, Tetley TD, Waterfield MD, Seckl MJ. Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. EMBO J 2002; 21: 5097–5108. DOI: 10.1093/emboj/cdf512
8. Boller D, Schramm A, Doepfner KT, Shalaby T, von Bueren AO, Eggert A et al. Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. Clin Cancer Res 2008; 14: 1172–1181. DOI: 10.1158/1078-0432.CCR-07-0737
9. Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M, Malek D et al. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 1995; 269: 690–693. DOI: 10.1126/science.7624799
10. Ning ZQ, Li J, Arceci RJ. Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells. Leuk Lymphoma 2001; 41: 513–522. DOI: 10.3109/10428190109060342
11. Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E et al. C-kit mutations in core binding factor leukemias. Blood 2000; 95: 726–727.
12. Tian Q, Frierson HF Jr, Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999; 154: 1643–1647. DOI: 10.1016/S0002-9440(10)65419-3
13. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12: 312–314. DOI: 10.1038/ng0396-312
14. Sakuma Y, Sakurai S, Oguni S, Satoh M, Hironaka M, Saito K. c-kit gene mutations in intracranial germinomas. Cancer Sci 2004; 95: 716–720. DOI: 10.1111/j.1349-7006.2004.tb03251.x
15. Hongyo T, Li T, Syaifudin M, Baskar R, Ikeda H, Kanakura Y et al. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res 2000; 60: 2345–2347.
16. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007; 138: 12–30. DOI: 10.1111/j.1365-2141.2007.06619.x
17. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473–481. DOI: 10.1158/0008-5472.CAN-05-2050
18. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008; 49: 615–619. DOI: 10.1080/10428190801896103
19. Hashimoto K, Matsumura I, Tsujimura T, Kim DK, Ogihara H, Ikeda H et al. Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation. Blood 2003; 101: 1094–1102. DOI: 10.1182/blood-2002-01-0177
20. Backer JM, Myers MG Jr, Shoelson SE, Chin DJ, Sun XJ, Miralpeix M et al. Phosphatidylinositol 3'-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J 1992; 11: 3469–3479. DOI: 10.1002/j.1460-2075.1992.tb05426.x
21. Sun J, Pedersen M, Rönnstrand L. Gab2 is involved in differential phosphoinositide 3-kinase signaling by two splice forms of c-Kit. J Biol Chem 2008; 283: 27444–27451. DOI: 10.1074/jbc.M709703200
22. Sun J, Pedersen M, Rönnstrand L. The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction. J Biol Chem 2009; 284: 11039–11047. DOI: 10.1074/jbc.M808058200
23. Longley BJ Jr, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96: 1609–1614. DOI: 10.1073/pnas.96.4.1609
24. Pardanani A. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 401–411. DOI: 10.1002/ajh.23459
25. Chian R, Young S, Danilkovitch-Miagkova A, Rönnstrand L, Leonard E, Ferrao P et al. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood 2001; 98: 1365–1373. DOI: 10.1182/blood.V98.5.1365
26. Harir N, Boudot C, Friedbichler K, Sonneck K, Kondo R, Martin-Lannerée S et al. Oncogenic kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood 2008; 112: 2463–2473. DOI: 10.1182/blood-2007-09-115477
27. Ogita S, Lorusso P. Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs. Target Oncol 2011; 6: 103–117. DOI: 10.1007/s11523-011-0176-7
28. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011; 13: 224. DOI: 10.1186/bcr3039
29. Cornillet-Lefebvre P, Cuccuini W, Bardet V, Tamburini J, Gillot L, Ifrah N et al. Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110delta mutations. Leukemia 2006; 20: 374–376. DOI: 10.1038/sj.leu.2404054
30. Czupalla C, Culo M, Müller EC, Brock C, Reusch HP, Spicher K et al. Identification and characterization of the autophosphorylation sites of phosphoinositide 3-kinase isoforms beta and gamma. J Biol Chem 2003; 278: 11536–11545. DOI: 10.1074/jbc.M210351200
31. Vanhaesebroeck B, Higashi K, Raven C, Welham M, Anderson S, Brennan P et al. Autophosphorylation of p110delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo. EMBO J 1999; 18: 1292–1302. DOI: 10.1093/emboj/18.5.1292
32. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011; 11: 865–878. DOI: 10.1038/nrc3143
33. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004; 279: 31655–31663. DOI: 10.1074/jbc.M403319200
34. Sadrzadeh H, Abdel-Wahab O, Fathi AT. Molecular alterations underlying eosinophilic and mast cell malignancies. Discov Med 2011; 12: 481–493.
35. Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006; 20: 965–970. DOI: 10.1038/sj.leu.2404188
36. Aichberger KJ, Sperr WR, Gleixner KV, Kretschmer A, Valent P. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest 2008; 38: 869–873. DOI: 10.1111/j.1365-2362.2008.02036.x
37. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008; 14: 3906–3915. DOI: 10.1158/1078-0432.CCR-08-0366
38. Cohen SM, Mukerji R, Timmermann BN, Samadi AK, Cohen MS. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers. Am J Surg 2012; 204: 895–901. DOI: 10.1016/j.amjsurg.2012.07.027
39. Nijenhuis CM, Haanen JB, Schellens JH, Beijnen JH. Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma? Cancer Treat Rev 2013; 39: 305–312. DOI: 10.1016/j.ctrv.2012.10.006
40. Blume-Jensen P, Siegbahn A, Stabel S, Heldin CH, Rönnstrand L. Increased Kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C. EMBO J 1993; 12: 4199–4209. DOI: 10.1002/j.1460-2075.1993.tb06104.x
41. Lundby A, Olsen JV. GeLCMS for in-depth protein characterization and advanced analysis of proteomes. Methods Mol Biol 2011; 753: 143–155. DOI: 10.1007/978-1-61779-148-2_10
42. Olsen JV, Schwartz JC, Griep-Raming J, Nielsen ML, Damoc E, Denisov E et al. A dual pressure linear ion trap Orbitrap instrument with very high sequencing speed. Mol Cell Proteomics 2009; 8: 2759–2769. DOI: 10.1074/mcp.M900375-MCP200
43. Cox J, Matic I, Hilger M, Nagaraj N, Selbach M, Olsen JV et al. A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics. Nat Protoc 2009; 4: 698–705. DOI: 10.1038/nprot.2009.36